Sean P Polster

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3941873/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Management of Intraventricular Hemorrhage. , 2022, , 1055-1065.e3.		0
2	Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions. Circulation Research, 2022, 130, 1204-1229.	4.5	109
3	Intracerebral Hemorrhage Volume Reduction and Timing of Intervention Versus Functional Benefit and Survival in the MISTIE III and STICH Trials. Neurosurgery, 2021, 88, 961-970.	1.1	24
4	In Reply: Intracerebral Hemorrhage Volume Reduction and Timing of Intervention Versus Functional Benefit and Survival in the MISTIE III and STICH Trials. Neurosurgery, 2021, 89, E247-E248.	1.1	2
5	Post-Trial Enhanced Deployment and Technical Performance with the MISTIE Procedure per Lessons Learned. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105996.	1.6	3
6	Phantom validation of quantitative susceptibility and dynamic contrastâ€enhanced permeability MR sequences across instruments and sites. Journal of Magnetic Resonance Imaging, 2020, 51, 1192-1199.	3.4	10
7	Symptomatic Brain Hemorrhages from Cavernous Angioma After Botulinum Toxin Injections, a Role of TLR/MEKK3 Mechanism? Case Report and Review of the Literature. World Neurosurgery, 2020, 136, 7-11.	1.3	7
8	In Reply: Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure. Neurosurgery, 2020, 86, E411-E411.	1.1	4
9	Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican. Journal of Experimental Medicine, 2020, 217, .	8.5	30
10	Thrombolysis for Evacuation of Intracerebral and Intraventricular Hemorrhage: A Guide to Surgical Protocols With Practical Lessons Learned From the MISTIE and CLEAR Trials. Operative Neurosurgery, 2020, 20, 98-108.	0.8	8
11	Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma. Nature Communications, 2020, 11, 2659.	12.8	27
12	Common transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation. GeroScience, 2020, 42, 1351-1363.	4.6	11
13	Cerebral Cavernous Malformation Proteins in Barrier Maintenance and Regulation. International Journal of Molecular Sciences, 2020, 21, 675.	4.1	20
14	Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance. Journal of Neurosurgery, 2020, 134, 1-8.	1.6	8
15	Phenotypic characterization of murine models of cerebral cavernous malformations. Laboratory Investigation, 2019, 99, 319-330.	3.7	24
16	Cavernous angiomas: deconstructing a neurosurgical disease. Journal of Neurosurgery, 2019, 131, 1-13.	1.6	87
17	Transcriptome clarifies mechanisms of lesion genesis versus progression in models of Ccm3 cerebral cavernous malformations. Acta Neuropathologica Communications, 2019, 7, 132.	5.2	27
18	Primary Sellar Paraganglioma: Case Report with Literature Review and Immunohistochemistry Resource. World Neurosurgery, 2019, 125, 32-36.	1.3	8

SEAN P POLSTER

#	Article	IF	CITATIONS
19	Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure. Neurosurgery, 2019, 84, 1157-1168.	1.1	93
20	Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet, The, 2019, 393, 1021-1032.	13.7	534
21	Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive <i>Pdcd10/Ccm3</i> Disease. Stroke, 2019, 50, 738-744.	2.0	40
22	Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation. Science Translational Medicine, 2019, 11, .	12.4	51
23	Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery, 2019, 85, 843-853.	1.1	58
24	Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice. Blood, 2019, 133, 193-204.	1.4	60
25	The cerebral cavernous malformation disease causing gene KRIT1 participates in intestinal epithelial barrier maintenance and regulation. FASEB Journal, 2019, 33, 2132-2143.	0.5	11
26	Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH). Neurosurgery, 2019, 84, 954-964.	1.1	34
27	Comprehensive transcriptome analysis of cerebral cavernous malformation across multiple species and genotypes. JCI Insight, 2019, 4, .	5.0	40
28	Biomarkers of cavernous angioma with symptomatic hemorrhage. JCI Insight, 2019, 4, .	5.0	25
29	Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. Circulation Research, 2018, 122, 1716-1721.	4.5	47
30	Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations. Translational Stroke Research, 2018, 9, 34-43.	4.2	45
31	Patients with cranial dural arteriovenous fistulas may benefit from expanded hypercoagulability and cancer screening. Journal of Neurosurgery, 2018, 129, 954-960.	1.6	13
32	Combined petrosal approach. Current Opinion in Otolaryngology and Head and Neck Surgery, 2018, 26, 293-301.	1.8	6
33	Convection-Enhanced Delivery of Polymeric Nanoparticles Encapsulating Chemotherapy in Canines with Spontaneous Supratentorial Tumors. World Neurosurgery, 2018, 117, e698-e704.	1.3	33
34	A Report of 2 Cases of Brainstem Hemorrhage After Suboccipital Craniectomy for Chiari Decompression. Operative Neurosurgery, 2018, 14, E58-E62.	0.8	1
35	An unusual presentation of dystonia and chorea from intraventricular pneumocephalus. , 2018, 9, 193.		4
36	Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy. Therapeutic Delivery, 2015, 6, 453-468.	2.2	8

SEAN P POLSTER

#	Article	IF	CITATIONS
37	Sprouty1 inhibits angiogenesis in association with up-regulation of p21 and p27. Molecular and Cellular Biochemistry, 2010, 338, 255-261.	3.1	31
38	Targeted Sprouty1 overexpression in cardiac myocytes does not alter myocardial remodeling or function. Molecular and Cellular Biochemistry, 2010, 342, 57-62.	3.1	1
39	Heart Failure–Associated Changes in RNA Splicing of Sarcomere Genes. Circulation: Cardiovascular Genetics, 2010, 3, 138-146.	5.1	137
40	Chronic Treatment with Clenbuterol Modulates Endothelial Progenitor Cells and Circulating Factors in a Murine Model of Cardiomyopathy. Journal of Cardiovascular Translational Research, 2009, 2, 182-190.	2.4	7
41	Sex and Age Dimorphism of Myocardial Gene Expression in Nonischemic Human Heart Failure. Circulation: Cardiovascular Genetics, 2008, 1, 117-125.	5.1	48
42	Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy. European Heart Journal, 2006, 28, 613-627.	2.2	102